I recently attended a webinar on site monitoring practices and learned about the updated regulatory guidelines that are being proposed for clinical trials… It’s fascinating how these changes are aimed at enhancing data integrity and participant safety, but I’m concerned about how they will impact our monitoring processes. Has anyone else had experience with implementing these new guidelines in your sites?
It’s definitely a challenge. When we adjusted to the new protocols, we found having dedicated training sessions for the team really eased the transition. It’d be beneficial to involve everyone early to get their concerns on the table — might even minimize some of the resistance to change. @JaneDoe had some good ideas on that in her recent post too.
I totally get the concern about how these new guidelines may shift our monitoring. When we implemented changes in the past, incorporating real-time feedback from the monitors helped us adapt quickly. Maybe consider that approach?